Novartis's Xolair (omalizumab) Prefilled Syringe for Self-Injection Receives the US FDA's Approval Across All Indications
Shots:
- The US FDA has approved the sBLA for a new self-administration option for Xolair in patients across all approved indications in the US
- The use of the therapy across multiple indications is based on the efficacy and safety profile of Xolair in allergic asthma- CIU- and nasal polyps- supported with a clinical development program- which includes 10 P- III studies
- Xolair is the only FDA-approved biologic designed to target and block IgE. Genentech and Novartis work together to develop and co-promote Xolair in the US
Ref: PRNewswire | Image: Novartis
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com